A 35-year-old woman from Mumbai with newly diagnosed classical Hodgkin lymphoma (mixed cellularity subtype) undergoes staging. CT chest shows a 7 cm anterior mediastinal mass with compression of the superior vena cava (SVC). Abdominal CT shows para-aortic lymphadenopathy. PET-CT confirms Stage IIIB disease. She has no B symptoms. What is the most appropriate next step in management?
A. Standard ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles with radiotherapy to mediastinum
B. Escalated BEACOPP chemotherapy (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) for 6–8 cycles
C. Immediate SVC stent placement followed by chemotherapy
D. Mediastinal mass biopsy to exclude primary mediastinal B-cell lymphoma (PMBL) before starting chemotherapy
Explanation
Clinical Context
This patient has intermediate-to-advanced stage cHL (Stage IIIB) with a bulky mediastinal mass causing SVC compression — a feature of unfavorable prognosis. The presence of bulky disease (≥7 cm) and advanced stage mandates intensified chemotherapy.
Risk Stratification in cHL
Key Point
Advanced-stage cHL with bulky disease (≥7 cm) or extranodal involvement is classified as unfavorable/high-risk and requires escalated chemotherapy (BEACOPP) rather than standard ABVD.
High-YieldNEET PG
Escalated BEACOPP (6–8 cycles) is superior to ABVD in advanced-stage cHL with unfavorable features, achieving 5-year PFS of 85–90% vs. 70–75% with ABVD alone.
Rationale for Escalated BEACOPP
1.
Higher dose intensity — BEACOPP delivers higher cumulative doses of alkylating agents and etoposide
2.
Superior efficacy in advanced disease — HD21 trial and other prospective studies show BEACOPP advantage in Stage III–IV disease
3.
Bulky mediastinal mass — requires aggressive systemic therapy; SVC compression is NOT an indication for immediate stenting before chemotherapy
4.
No B symptoms — favorable prognostic factor within the unfavorable stage category
Management of SVC Compression
Chemotherapy-first approach — BEACOPP is initiated; most bulky masses respond rapidly (within 1–2 cycles)
SVC stent — reserved for refractory/progressive SVC obstruction despite chemotherapy; not needed upfront
Supportive care — elevate head of bed, diuretics, consider low-dose corticosteroids if severe symptoms
Clinical Pearl
Bulky mediastinal masses in cHL often show dramatic response to chemotherapy alone; invasive procedures (stenting, biopsy) should be deferred unless chemotherapy fails or complications develop.
Why Not the Other Options?
Table
Option
Why Incorrect
Immediate SVC stent
SVC stenting is NOT first-line; chemotherapy is initiated first. Stenting is reserved for refractory obstruction or acute decompensation.
Standard ABVD 4 cycles
ABVD is insufficient for advanced-stage unfavorable cHL. Escalated BEACOPP (6–8 cycles) is the standard of care for Stage III–IV disease.
Mediastinal mass biopsy
Biopsy is unnecessary; diagnosis is already confirmed by lymph node biopsy. PMBL is a separate entity (CD20+, EBV−, lacks RS cells). No re-biopsy needed before treatment.
Harrison 21e Ch 104
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
